Global Fund’s new HIV and TB multicountry grants in Eastern Europe and Central Asia begin implementation
The Global Fund Board has recently approved several multicountry grants, whose aim is to address priorities “deemed critical to fulfil the aims of the Global Fund 2017-2022 strategy,” and to address needs that are not being fulfilled by national (single country) allocations.
On 17 August 2018 and on 26 October 2018, the Global Fund Board approved two HIV grants and three TB grants worth $28.1 million. The Board also approved $15.9 million in matching funds requests for six components.
The HIV story in Romania has been marked by several dramatic episodes. The first was in the late 1980s, when thousands of children became infected with HIV through a dramatic nosocomial HIV epidemic, predominantly among orphans and hospitalized children. The voices of parents and many supporters then led to the introduction of the country’s large treatment programs – early on with donor support – to provide HIV treatment to all in need.
According to four case studies recently published by the Eurasian Harm Reduction Network (EHRN), the readiness to transition harm reduction programs from Global Fund support to domestic funding in four countries in Eastern Europe and Central Asia ranges from 19% to 47%.
The four countries are Albania, Bosnia and Herzegovina, Macedonia, and Romania. See the table for further details.
In anticipation of The Global Fund’s new strategy (2017-2022), many are calling for clarity on how the Fund will ensure the sustainability of its investments. This is particularly relevant as the Fund transitions out of many upper-middle-income countries.